December 23, 2022 Acad, Gov/Utilities FDA approves Roche’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma Read more
December 21, 2022 Acad, Gov/Utilities Clinical Research/Diagn. Microscopy FDA approves Roche’s Actemra for the treatment of COVID-19 in hospitalised adults Read more
December 14, 2022 M&A, Partnerships Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options Read more
December 12, 2022 Product Launch Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma Read more
December 12, 2022 Product Launch Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022 Read more
December 12, 2022 Uncategorized [Ad hoc announcement pursuant to Art. 53 LR] Roche: Changes in the Board of Directors and the Corporate Executive Committee Read more
November 16, 2022 Acad, Gov/Utilities PR/Corporate Roche receives U.S. FDA Emergency Use Authorization for its high-throughput test to detect monkeypox virus Read more
November 14, 2022 Bio/Pharma/CRO [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease Read more
November 3, 2022 Acad, Gov/Utilities Product Launch Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs Read more
October 27, 2022 Bio/Pharma/CRO Positive topline phase III results show Roche's Vabysmo improved vision for people living with retinal vein occlusion (RVO) Read more
